Literature DB >> 11922398

Parenteral troxerutin and carbazochrome combination in the treatment of post-hemorrhoidectomy status: a randomized, double-blind, placebo-controlled, phase IV study.

M Basile1, S Gidaro, M Pacella, P M Biffignandi, G S Gidaro.   

Abstract

Flavonoids, such as troxerutin, have been shown to be safe and effective agents for the treatment of chronic venous insufficiency. The fixed combination between troxerutin 150 mg and carbazochrome 1.5 mg (Fleboside ampoules) was previously shown to have a good efficacy and safety profile in non-surgical patients with acute uncomplicated hemorrhoids. The purpose of this randomized, double-blind, placebo-controlled study was to investigate the efficacy and tolerability of the active combination in the treatment of post-hemorrhoidectomy patients. 30 patients were randomized to receive one of two treatments: troxerutin 150 mg and carbazochrome 1.5 mg, or placebo, i.m. 3 ml ampoules twice a day for five consecutive days after the surgical procedure, starting from the day of surgery. Efficacy parameters were assessed as follows: at baseline (T1), after the first administration (T2; day of surgery), the second day after the surgical procedure (T3), and the fifth day after the surgical procedure (T4); hemorrhoidal symptoms based on a visual analogue scale (VAS): pain, discharge, bleeding, inflammation, and pruritus; analgesic intake, if any; time to restore a physiological defecation; edema evaluation (based on a four-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe); camera pictures taken at T1 and T4 (in selected patients); and blood coagulation tests. Analysis between treatment groups revealed a highly significant difference at T3 and T4 for the total VAS score (p = 0.007 and p = 0.001, respectively) in favor of the active combination treatment. A statistically significant difference was also observed for bleeding and pruritus at T3 and for these two parameters and both inflammation and edema at T4 (p < 0.001) in favor of the active combination group. No adverse events were reported. Neither the active combination nor placebo affected blood coagulation tests. We conclude that intramuscular administration of the fixed combination of troxerutin 150 mg and carbazochrome 1.5 mg is effective, well tolerated and superior to placebo in improving hemorrhoidal and post-surgical symptoms during the five days following surgery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11922398

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  4 in total

1.  Prospective multicenter study of visual outcomes following three different treatments for macular edema associated with branch retinal vein occlusion: a study by the Japanese BRVO study group.

Authors:  Seiyo Harino; Kenichiro Bessho; Teruyo Kida
Journal:  Jpn J Ophthalmol       Date:  2012-02-23       Impact factor: 2.447

Review 2.  Drug treatment of haemorrhoids.

Authors:  Mahesh C Misra
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Protection of cellular DNA from gamma-radiation-induced damages and enhancement in DNA repair by troxerutin.

Authors:  Dharmendra Kumar Maurya; Sreedevi Balakrishnan; Veena Prakash Salvi; Cherupally Krishnan Krishnan Nair
Journal:  Mol Cell Biochem       Date:  2005-12       Impact factor: 3.396

4.  Combining an in silico approach with an animal experiment to investigate the protective effect of troxerutin for treating acute lung injury.

Authors:  Ying Li; Pan Ma; Jin Fu; Jingjing Wu; Xue Wu
Journal:  BMC Complement Altern Med       Date:  2019-06-10       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.